Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,063,633
  • Shares Outstanding, K 85,720
  • Annual Sales, $ 55,210 K
  • Annual Income, $ -109,750 K
  • 36-Month Beta N/A
  • Price/Sales 54.50
  • Price/Cash Flow N/A
  • Price/Book 10.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate -0.63
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.81
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.89 +28.15%
on 07/18/18
40.75 -12.29%
on 08/07/18
+7.27 (+25.54%)
since 07/16/18
3-Month
21.44 +66.70%
on 06/11/18
40.75 -12.29%
on 08/07/18
+12.93 (+56.69%)
since 05/16/18
52-Week
13.85 +158.05%
on 08/18/17
40.75 -12.29%
on 08/07/18
+21.39 (+149.06%)
since 08/16/17

Most Recent Stories

More News
Akcea Reports Financial Results and Highlights for Second Quarter 2018

TEGSEDI(TM) (inotersen) Approved in European Union

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
Akcea Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Akcea Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time....

AKCA : 35.74 (+1.82%)
Akcea Announces Publication of Study Results Showing Multiple Benefits of Patient-to-Patient Connectivity in FCS

Results from the first-ever study evaluating quality of life in people with FCS and impact of patient connectivity published in Expert Opinion on Orphan Drugs.

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
Akcea Therapeutics Reaches Analyst Target Price

In recent trading, shares of Akcea Therapeutics Inc have crossed above the average analyst 12-month target price of $32.00, changing hands for $32.46/share. When a stock reaches the target an analyst...

AKCA : 35.74 (+1.82%)
Akcea Therapeutics to Hold Second Quarter 2018 Financial Results Webcast

Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Monday, August 6 at 4:30 p.m. Eastern Time to discuss its second...

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.

ADXS : 1.44 (+0.70%)
ARRY : 14.21 (+3.50%)
AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
AMGN : 196.44 (+0.60%)
Akcea and Ionis Announce Approval of TEGSEDI(TM) (inotersen) in the European Union

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that TEGSEDI (inotersen) has received marketing authorization...

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics (Nasdaq: AKCA), announced today that the final study results from NEURO-TTR, the...

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion...

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)
Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis

Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation ("Ambry"), a Konica Minolta company, today announced the launch of hATTR Compass(TM),...

AKCA : 35.74 (+1.82%)
IONS : 51.42 (+3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 37.42
1st Resistance Point 36.58
Last Price 35.74
1st Support Level 34.59
2nd Support Level 33.44

See More

52-Week High 40.75
Last Price 35.74
Fibonacci 61.8% 30.47
Fibonacci 50% 27.30
Fibonacci 38.2% 24.13
52-Week Low 13.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar